Elenco degli articoli con argomento «Dupilumab»

Dermatologia

29 set 2023

Efficacy and safeness of tralokinumab in patients with atopic dermatitis

Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series

31 ago 2023

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib

Characterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed.

05 giu 2023

Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis

Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s

17 apr 2023

The impact of dupilumab

Skin barrier dysfunction plays an important role in atopic dermatitis (AD) aetiopathogenesis

20 feb 2023

Treatment of Severe Atopic Dermatitis with Dupilumab

Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease.

13 dic 2022

Comparison of real-world treatment outcomes of systemic immunomodulating

Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.

07 dic 2022

Treatment of chronic hand eczema with dupilumab

Treatment of chronic hand eczema with dupilumab - a retrospective follow-up study

03 ott 2022

Dupilumab in children aged 6 months to younger than 6 years

Background Current systemic treatments for children younger than 6 years with moderate-to-severe atopic dermatitis

15 set 2022

Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus

Dupilumab has demonstrated a great reduction in chronic pruritus that is the hallmark of atopic dermatitis

09 mag 2022

Moderate-to-severe atopic dermatitis in adolescents

Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease and its treatment can be very challenging

18 apr 2022

Th2 IL-4/IL-13 dual blockade with Dupilumab is linked to some Emergent

Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative inflammatory arthritis and psoriasis that form part of the spondyloarthropathy (SpA) spectrum.

11 ott 2021

Phase 2a randomized clinical trial of dupilumab

Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited

29 mar 2021

Treatment of Grover Disease With Dupilumab

Treatment of Grover Disease With Dupilumab

04 mar 2021

A 48-week update

A 48-week update of a multicentre real-life experience of dupilumab in adult patients

24 feb 2021

A Short Cycle of Narrow-Band UVB

Since the best clinical response to dupilumab is achieved after 12-16 weeks

11 nov 2020

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis navigation-next-alternate

Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one‐year observational cohort study of the first 100 patients treated

20 ott 2020

Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

Dupilumab, an inhibitor of interleukin (IL)‐4/13 activity, is a biological agent approved for the treatment of moderate‐to‐severe atopic dermatitis (AD)

14 set 2020

A phase 2, open‐label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis

pharmacokinetics, safety and efficacy

15 giu 2020

Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo

Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.

10 mag 2020

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

A Systematic Review and Network Meta-analysis